-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pexidartinib Hydrochloride in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pexidartinib Hydrochloride in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pexidartinib Hydrochloride in Sarcomas Drug Details: Pexidartinib hydrochloride (Turalio) is an anti-neoplastic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pexidartinib Hydrochloride in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pexidartinib Hydrochloride in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pexidartinib Hydrochloride in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masitinib in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masitinib in Asthma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masitinib in Asthma Drug Details: Masitinib (AB-1010) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Masitinib in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masitinib in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masitinib in Peritoneal Cancer Drug Details: Masitinib (AB-1010) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OpSCF in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OpSCF in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OpSCF in Atopic Dermatitis (Atopic Eczema) Drug Details: Monoclonal antibodies...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Refractory Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Relapsed Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib Mesylate in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma...